Role of new antifungal agents in prophylaxis of mycoses in high risk patients

被引:20
|
作者
van Burik, JAH [1 ]
机构
[1] Univ Minnesota, Minneapolis, MN 55455 USA
关键词
aerosolized amphotericin; fluconazole; fungal infection; hematopoietic stem cell transplantation; itraconazole; liver transplantation; lung transplantation; micafungin; mycoses; pancreas transplantation; posaconazole; prophylaxis; voriconazole;
D O I
10.1097/01.qco.0000185984.57135.ad
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of review For pancreas, liver, and hematopoietic stem cell transplant recipients, no antifungal prophylaxis led to a high rate of and high morbidity from fungal infection. With the use of fluconazole as prophylaxis since the early 1990s, there have been shifts in the types of infecting fungal pathogens, documentation of resistance among fungal organisms, and changes in transplant practices. The aim of this article is to review recent clinical trials regarding antifungal chemoprophylaxis among several populations of high risk patients. Recent findings Itraconazole, micafungin, and posaconazole have been studied as alternatives to fluconazole prophylaxis. Itraconazole showed no dramatic improvement over fluconazole as prophylaxis during liver and hematopoietic stem cell transplantation, primarily due to gastrointestinal side effects. In addition, detrimental changes to cyclophosphamide metabolism were noted for hematopoietic stem cell transplant recipients. Micafungin was superior to fluconazole during the pre-engraftment period of hematopoietic stem cell transplantation, because it was able to prevent mold infections, required less switches to empirical antifungal therapy, and functioned as well as fluconazole in preventing yeast infections. Posaconazole was compared to fluconazole during a 16-week prophylaxis period during graft-versus-host disease, but results of this study are still forthcoming. Aerosolized amphotericin products appear to be safe for lung transplant recipients. Summary Fluconazole remains the standard agent for prophylaxis against invasive fungal infections for pancreas, liver, and hematopoietic stem cell transplant recipients. Micafungin is superior to fluconazole with minimal toxicity for use in the pre-engraftment period of hematopoietic stem cell transplantation. The optimal agent for prophylaxis later following transplant, if mold coverage is desired during prolonged immunosuppression, has not been determined.
引用
收藏
页码:479 / 483
页数:5
相关论文
共 50 条
  • [1] Antifungal prophylaxis for invasive mycoses in high risk patients
    Ullmann, Andrew J.
    Cornely, Oliver A.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (06) : 571 - 576
  • [2] Inhaled Antifungal Agents for the Treatment and Prophylaxis of Pulmonary Mycoses
    Liao, Qiuying
    Lam, Jenny K. W.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (12) : 1453 - 1468
  • [3] NEW ANTIFUNGAL AGENTS FOR THE SYSTEMIC MYCOSES
    RINGEL, SM
    [J]. MYCOPATHOLOGIA, 1990, 109 (02) : 75 - 87
  • [4] ORAL MYCOSES AND ANTIFUNGAL AGENTS
    HOLMBERG, K
    [J]. SWEDISH DENTAL JOURNAL, 1980, 4 (1-2) : 53 - 61
  • [5] Laboratory evaluation of new antifungal agents against rare and refractory mycoses
    Sutton, DA
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2002, 15 (06) : 575 - 582
  • [6] EFECTIVENESS OF ANTIFUNGAL PROPHYLAXIS WITH NEW AGENTS COMBINED WITH A DIAGNOSTIC-DRIVEN ANTIFUNGAL THERAPY STRATEGY IN HIGH-RISK NEUTROPENIC PATIENTS. A SINGLE-PROSPECTIVE STUDY
    Marcellini Antonio, S.
    Garcia Suarez, J.
    Gil Fernandez, J. J.
    Arribas, I.
    Gutierrez, I.
    Juarez, L. M.
    Casco, C.
    Cortti, M. J.
    Lopez, M.
    Callejas, M.
    Pascual, T.
    Martin, Y.
    Magro, E.
    Calero, M. A.
    Perera, F.
    Flores, E.
    Burgaleta, C.
    [J]. HAEMATOLOGICA, 2014, 99 : 748 - 748
  • [7] Role of Echinocandins as Antifungal Prophylaxis Agents in Lung Transplant Recipients
    Pavan, R.
    Husain, S.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S239 - S240
  • [8] Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective
    Lamoth, Frederic
    Lewis, Russell E.
    Kontoyiannis, Dimitrios P.
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 75 (03) : 534 - 544
  • [9] COMMONLY USED ANTIFUNGAL AGENTS IN THE TREATMENT OF SYSTEMIC MYCOSES
    BERENGUER, JB
    [J]. REVISTA CLINICA ESPANOLA, 1995, 195 : 58 - 65
  • [10] ANTIFUNGAL AGENTS IN THE TREATMENT OF MYCOSES OF THE SKIN AND THE NAILS OF THE FEET
    POLANO, MK
    [J]. TGO-TIJDSCHRIFT VOOR THERAPIE GENEESMIDDEL EN ONDERZOEK JDR-JOURNAL FOR DRUGTHERAPY AND RESEARCH, 1991, 16 (06): : 185 - 187